IMMUNEERING CORPORATION - CLASS A COMMON STOCK

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

14 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

05 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

20 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Immuneering Announces Participation in February Investor Conferences

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

20 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

12 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Morgan Stanley Healthcare Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

03 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Healthcare Conference

30 May 2023 07:00:01 By Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

04 May 2023 15:05:02 By Nasdaq GlobeNewswire

Immuneering Announces $30 Million Underwritten Offering

18 Apr 2023 08:24:15 By Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

18 Apr 2023 08:00:02 By Nasdaq GlobeNewswire